RxDoctor Payments DataLook up a doctor →

Keith Skubitz, MD

Medical Oncology · Minneapolis, MNNPI 1215019203

Payments from drug & device makers

$1,105,029in general payments, 2019–2025

Across 418 payments — averaging $2643.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Deciphera Pharmaceuticals Inc.$826K
  • Amgen$257K
  • Boehringer Ingelheim$20K
  • Bayer$1K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$553
  • Tempus AI, Inc$151
  • plus $18 from 1 others

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,105,029 in reported general payments places this provider in the 75th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$19,281
Medicare patients
65
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →